A
Anew Labs
Adjacent neolabAI drug discovery: structure prediction, molecule and antibody design models, and its own drug programmes
Raised, confirmed$290M1 confirmed round
Valuation, confirmed—none disclosed
Valuation, reported$1.5B17 Sep 2026, not confirmed
Founded2026Shanghai, CN
Key facts
| Field | Value | Source · checked |
|---|---|---|
| Classification | Adjacent neolabAI drug-discovery company spun out of ByteDance's AI-for-science team; ByteDance keeps a majority stake | |
| Field | AI for science | |
| Founded | Jun 2026 | eu.36kr.com until June 2026, when it officially broke away from the large tech company system and became the independent Anew Labschecked 15 Nov 2026 |
| Headquarters | Shanghai, CN | technode.global Anew Labs is headquartered in Shanghai and also has offices in Singapore and San Francisco.checked 15 Nov 2026 |
| Founders | Liu Kai | |
| Website | anewbt.com | anewbt.com Anew Labs is an AI pharmaceutical company building AI-powered drug discovery platforms for protein structure prediction, molecule generation, antibody design and R&D decision-making.checked 15 Nov 2026 |
| Careers | anewbt.com | anewbt.comchecked 15 Nov 2026 |
Funding rounds
Anew Labs has raised $290M in rounds confirmed by the company, a regulator or two independent outlets. Sources disagree on at least one confirmed round, so the total may count some money twice; see the note on that round. Status rules: methodology.
| Date | Round | Amount | Valuation | Investors | Status | Source · checked |
|---|---|---|---|---|---|---|
| 17 Sep 2026 | Angel | $290M | $1.5B | Lead: HSG, IDG Capital, Hillhouse Investment, 5Y Capital; Hillhouse Investment (GL Ventures), Gaorong Ventures, Primavera Venture Partners, Boyu Capital, Shanghai Future Industries Fund, SBP Group, China Biopharmaceuticals, Chunhua Capital | Confirmedsources conflict | TechNode (citing Reuters) Anew Labs, an artificial intelligence drug-discovery business spun out of ByteDance, has raised $290 million in its first external funding round at a valuation of about $1.5 billion.+2 more sourceschecked 15 Nov 2026 |
Notes on these rounds
- 17 Sep 2026 Angel: First external round after the June 2026 spin-off from ByteDance, which retains a 56% stake (Reuters). Round reported by Reuters citing sources and by Economic Observer, which interviewed participating investors; Anew Labs did not comment. Investor lists differ between the two reports.
People
| Name | Role | Before | Now | Source · checked |
|---|---|---|---|---|
| Liu Kai | Head of Anew Labs | ByteDance (Head of AI-for-science / AI drug discovery team), IDG Capital (Venture investor) | Current | eu.36kr.com In 2021, Liu Kai led the team to form the AI pharmaceutical team, with about 50 core memberschecked 15 Nov 2026 |
Professional facts from public sources only. How people records are handled.
What it has shipped
| Name | Kind | Date | Open weights | Source · checked |
|---|---|---|---|---|
| AnewFold | model | No | anewbt.com Anew Labs offers a suite of AI models for biomolecular structure prediction and designchecked 15 Nov 2026 | |
| Protenix | model | 2025 | Yes | en.wowtale.net Its open-sourced structure-prediction model, Protenix, released in 2025checked 15 Nov 2026 |
| AnewDesign | product | No | ||
| AnewMind | model | No | technode.global AnewMind, a scientific reasoning large language model focused on drug-discovery decisionschecked 15 Nov 2026 |
Work at Anew Labs, or see something wrong? Update this profile with a public source. How corrections work.